Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k).
Farr A, Effendy I, Frey Tirri B, Hof H, Mayser P, Petricevic L, Ruhnke M, Schaller M, Schaefer APA, Sustr V, Willinger B, Mendling W.
Mycoses. 2021 Jun;64(6):583-602. doi: 10.1111/myc.13248. Epub 2021 Feb 27.
Candidiasis (vulvovaginal).
Martin Lopez JE.
BMJ Clin Evid. 2015 Mar 16;2015:0815.
Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
Martens MG, Maximos B, Degenhardt T, Person K, Curelop S, Ghannoum M, Flynt A, Brand SR.
Am J Obstet Gynecol. 2022 Dec;227(6):880.e1-880.e11. doi: 10.1016/j.ajog.2022.07.023. Epub 2022 Jul 19.
Acute vulvovaginitis.
Shirley RL.
N Engl J Med. 2006 Dec 28;355(26):2791; author reply 2791. doi: 10.1056/NEJMc062854.
Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.
MacAlpine J, Lionakis MS.
Cell Host Microbe. 2024 Oct 9;32(10):1654-1667. doi: 10.1016/j.chom.2024.08.018.
Candidiasis (vulvovaginal).
Spence D.
BMJ Clin Evid. 2010 Jan 5;2010:0815.
Candidiasis (vulvovaginal).
Spence D.
BMJ Clin Evid. 2007 Feb 1;2007:0815.
Ibrexafungerp to treat acute vulvovaginal candidiasis.
Masone MC.
Nat Rev Urol. 2021 Nov;18(11):638. doi: 10.1038/s41585-021-00522-9.
Recurrent vulvovaginal candidiasis.
Ringdahl EN.
Mo Med. 2006 Mar-Apr;103(2):165-8.
Probiotics: "living drugs".
Elmer GW.
Am J Health Syst Pharm. 2001 Jun 15;58(12):1101-9. doi: 10.1093/ajhp/58.12.1101.
